# A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

> **NCT02061761** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 106 (actual)

## Conditions studied

- Hematologic Neoplasms

## Interventions

- **BIOLOGICAL:** BMS-986016
- **BIOLOGICAL:** BMS-936558

## Key facts

- **NCT ID:** NCT02061761
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-13
- **Primary completion:** 2022-02-16
- **Final completion:** 2022-02-16
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02061761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02061761, "A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02061761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*